Back to the main directory
Company Analysis / Equity
- CERC: Encouraging Results from Proof-of- Concept Study of CERC-501 in MDD… by Zacks
- CYRX: Biopharma, Clinical Trial Growth, Fuels Another Record Quarter by Zacks
- TSEM: 2017 on Track, Capacity Plans Need to Be Addressed By Year End by Zacks
- Strong Start for Lanxess in 1Q, but Not Sustainable; Shares Overvalued by Morningstar
- Disappointing Q1 but there is a reserve of growth in mature markets by AlphaValue
- Uplift in Crude Prices Benefits Eni; Positive Results in Gas and Power Thanks to Renegotiations by Morningstar
- Quantum leap by Edison Investment Research
- Good progress, cautious outlook by Edison Investment Research
- Myer Holdings (Not - Rated) Q3 17A sales update (Read through for WHL's David Jones and Country Road) by Arqaam Capital
- Ctrip’s Margins Continue to Improve; Shares Fairly Valued by Morningstar
- We raise our FVE for Tiffany & Co to $85 to reflect U.S. tax reform. Shares modestly overvalued. by Morningstar
- Full steam into 2017 and strong guidance given by AlphaValue
- La dynamique est toujours là by MidCap Partners
- Petite acqusition en Allemagne by MidCap Partners
- Symantec’s Integration Efforts Will Yield Much Better Profitability in FY2018; Raising FVE to $20 by Morningstar
- KBC's Numbers Reflect Another Good Quarter; Core Operational Performance Intact by Morningstar
- Board Shakeup to Diminish Our Stewardship Rating for Whole Foods, Overshadows Turnaround Plan by Morningstar
- Foundations remain strong in Spain despite a disappointing Q1 by AlphaValue
- strong set of 1Q17 results, with 6% beat on EBITDA and 64% beat on NI by Wood and Company
- Return to Organic Growth Just Around the Corner for CI Financial by Morningstar
- As usual a good Q1 release (in particular in the US) by AlphaValue
- Ingersoll-Rand Reveals 2020 Financial Targets at Its Investor Day; We Reiterate Our $84 FVE by Morningstar
- Henkel Delivers Another Strong Quarter; Raising Valuation , but Challenges Loom by Morningstar
- Strong Q1 including one-offs, while acquisitions continued at a high pace by AlphaValue
- We've Raised Our Takeda Fair Value Estimate, but Concerns Remain on Competitive Landscape by Morningstar